(Q24247996)

29 July 2017

1 reference

title

Nebulised anti-pseudomonal antibiotics for cystic fibrosis (English)

1 reference

29 July 2017

0 references

0 references

Gerard Ryan

1

0 references

Somnath Mukhopadhyay

2

0 references

Meenu Singh

3

0 references

G Ryan

1

1 reference

29 July 2017

S Mukhopadhyay

2

1 reference

29 July 2017

M Singh

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

21 July 2003

0 references

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

29 July 2017

2003

0 references

published in

1 reference

29 July 2017

CD001021

1 reference

29 July 2017

2

1 reference

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

29 July 2017

3

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

New clinical evidence from the European tobramycin trial in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Aerosol delivery of antibiotics to the lower airways of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

The long-term use of inhaled tobramycin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Microbiological and immunologic considerations with aerosolized drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Administration of aerosolized antibiotics in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Defining a pulmonary exacerbation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Bronchial constriction and inhaled colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Inhaled antibiotics in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Randomized trials stopped early for benefit: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Aerosol deposition considerations in inhalation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Nebulised hypertonic saline for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

Long-term tobramycin aerosol therapy in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001021

7 January 2021

10.1002/14651858.CD001021

Identifiers

DOI

1 reference

29 July 2017

1 reference